UB Paderborn / Katalog / Suche / in CDI

Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection

Toxins, 2022-01, Vol.14 (1), p.64

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands

International journal of molecular sciences, 2023-12, Vol.24 (23), p.16845

2023

Link zum Volltext

Verfügbarkeit prüfen

Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept

Nuclear Medicine and Molecular Imaging , 2018, 52(1), , pp.80-81

2018

Link zum Volltext

Verfügbarkeit prüfen

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation

Diagnostics (Basel), 2022-08, Vol.12 (8), p.1926

2022

Link zum Volltext

Verfügbarkeit prüfen

Incidental Finding of Colon Carcinoma Related to High Uptake in 18F-PSMA-1007 PET

Clinical nuclear medicine, 2020-07, Vol.45 (7), p.561

2020

Link zum Volltext

Verfügbarkeit prüfen

First-in-human study of a novel somatostatin receptor antagonist 68Ga-NODAGA-LM3 for molecular imaging of paraganglioma patients

The Journal of nuclear medicine (1978), 2019-05, Vol.60

2019

Link zum Volltext

Verfügbarkeit prüfen

Utility of 18 F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology

Journal of Nuclear Medicine, 2022-09, Vol.63 (9), p.1334-1342

2022

Link zum Volltext

Verfügbarkeit prüfen

Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen

British journal of radiology, 2018-11, Vol.91 (1091), p.20180308-20180308

2018

Link zum Volltext

Verfügbarkeit prüfen

Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer

The Journal of nuclear medicine (1978), 2018-05, Vol.59, p.529

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Role of 68 Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy

Journal of Nuclear Medicine, 2023-06, Vol.64 (6), p.896-901

2023

Link zum Volltext

Verfügbarkeit prüfen

The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data

The Journal of nuclear medicine (1978), 2022-05, Vol.63 (5), p.742-745

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Detoxsan ® powder on diarrhea caused by gastrointestinal neuroendocrine tumors

World journal of gastroenterology : WJG, 2019-05, Vol.25 (17), p.2133-2143

2019

Link zum Volltext

Verfügbarkeit prüfen

A rare case of polyostotic fibrous dysplasia detected on 18 F-rhPSMA-7 PET/CT

European journal of nuclear medicine and molecular imaging, 2020-11, Vol.47 (12), p.2927

2020

Link zum Volltext

Verfügbarkeit prüfen

Salivary gland toxicity after PRLT using Lu-177 PSMA in patients with advanced prostate cancer: A single-center systematic investigation

The Journal of nuclear medicine (1978), 2019-05, Vol.60

2019

Link zum Volltext

Verfügbarkeit prüfen

Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?

The Journal of nuclear medicine (1978), 2019-05, Vol.60

2019

Link zum Volltext

Verfügbarkeit prüfen

Radioligand therapy using combination of Ac-225 and Lu-177 labelled PSMA ligands for progressive end-stage metastatic prostate cancer: effective trade-off between response and toxicity

The Journal of nuclear medicine (1978), 2019-05, Vol.60

2019

Link zum Volltext

Verfügbarkeit prüfen

The Influence of Specific Activity on the Biodistribution of 18 F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data

Journal of Nuclear Medicine, 2021-08, p.jnumed.121.262471

2021

Link zum Volltext

Verfügbarkeit prüfen

MP62-17 DIAGNOSTIC EFFICACY OF 18 F-RHPSMA-7.3 IMAGING FOR N-STAGING PATIENTS WITH HIGH-RISK PROSTATE CANCER

The Journal of urology, 2020-04, Vol.203 (Supplement 4)

2020

Link zum Volltext

Verfügbarkeit prüfen

18 F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy

Journal of Nuclear Medicine, 2020-05, Vol.61 (5), p.696-701

2020

Link zum Volltext

Verfügbarkeit prüfen

18 F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study

Journal of Nuclear Medicine, 2022-08, Vol.63 (8), p.1208-1214

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparative Analysis of Morphological and Functional Effects of [sup.225]Ac- and [sup.177]Lu-PSMA Radioligand Therapies on Salivary Glands

International journal of molecular sciences, 2023-11, Vol.24 (23)

2023

Link zum Volltext

Verfügbarkeit prüfen

Injection of botulinum toxin for preventing salivary gland toxicity after PSMA-Radio-Ligand-Therapy - an empiric proof of a promising concept

The Journal of nuclear medicine (1978), 2018-05, Vol.59, p.525

2018

Link zum Volltext

Verfügbarkeit prüfen

PET/CT imaging of somatostatin receptor expressing solid tumors with the novel somatotostatin receptor antagonist ^sup 68^Ga-NODAGA-LM3

The Journal of nuclear medicine (1978), 2018-05, Vol.59, p.42

2018

Link zum Volltext

Verfügbarkeit prüfen

PET/CT imaging of somatostatin receptor expressing solid tumors with the novel somatotostatin receptor antagonist 68Ga-NODAGA-LM3

The Journal of nuclear medicine (1978), 2018-05, Vol.59, p.42

2018

Link zum Volltext

Verfügbarkeit prüfen

Positive Predictive Value and Correct Detection Rate of 18 F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard

Journal of Nuclear Medicine, 2021-07, Vol.62 (7), p.968-974

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection

Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands

Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation

Incidental Finding of Colon Carcinoma Related to High Uptake in 18F-PSMA-1007 PET

First-in-human study of a novel somatostatin receptor antagonist 68Ga-NODAGA-LM3 for molecular imaging of paraganglioma patients

Utility of 18 F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology

Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen

Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer

Prognostic Role of 68 Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy

The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data

Efficacy of Detoxsan ® powder on diarrhea caused by gastrointestinal neuroendocrine tumors

A rare case of polyostotic fibrous dysplasia detected on 18 F-rhPSMA-7 PET/CT

Salivary gland toxicity after PRLT using Lu-177 PSMA in patients with advanced prostate cancer: A single-center systematic investigation

Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?

Radioligand therapy using combination of Ac-225 and Lu-177 labelled PSMA ligands for progressive end-stage metastatic prostate cancer: effective trade-off between response and toxicity

The Influence of Specific Activity on the Biodistribution of 18 F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data

MP62-17 DIAGNOSTIC EFFICACY OF 18 F-RHPSMA-7.3 IMAGING FOR N-STAGING PATIENTS WITH HIGH-RISK PROSTATE CANCER

18 F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy

18 F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study

Comparative Analysis of Morphological and Functional Effects of [sup.225]Ac- and [sup.177]Lu-PSMA Radioligand Therapies on Salivary Glands

Injection of botulinum toxin for preventing salivary gland toxicity after PSMA-Radio-Ligand-Therapy - an empiric proof of a promising concept

PET/CT imaging of somatostatin receptor expressing solid tumors with the novel somatotostatin receptor antagonist ^sup 68^Ga-NODAGA-LM3

PET/CT imaging of somatostatin receptor expressing solid tumors with the novel somatotostatin receptor antagonist 68Ga-NODAGA-LM3

Positive Predictive Value and Correct Detection Rate of 18 F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard

Aktive Filter

Suchergebnisse filtern